Orsini Selected as the Exclusive Specialty Pharmacy and Home Infusion Partner for Denali Therapeutics' AVLAYAH™ (tividenofusp alfa-eknm) [Yahoo! Finance]
Denali Therapeutics Inc. (DNLI)
Last denali therapeutics inc. earnings: 8/6 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.denalitherapeutics.com
Company Research
Source: Yahoo! Finance
ELK GROVE VILLAGE, Ill. April 20, 2026 /PRNewswire/ -- Orsini, a leader in rare disease pharmacy solutions, announced today that it is the exclusive specialty pharmacy partner for Denali Therapeutics' AVLAYAH™ (tividenofusp alfa-eknm), an FDA-approved enzyme replacement therapy for the treatment of neurologic manifestations of Hunter syndrome (mucopolysaccharidosis type II, or MPS II) when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment.. Read the full Prescribing Information here . As part of this program, Orsini will provide comprehensive home infusion support to ensure patients can access therapy in the comfort and convenience of their own homes, as recommended and supervised by a healthcare provider. Orsini - Rare Disease Pharmacy Solutions (PRNewsfoto/Orsini Healthcare) MPS II is a genetic metabolic condition in which the body does not produce enough of the enzymes required to break down sugars into
Show less
Read more
Impact Snapshot
Event Time:
DNLI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNLI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNLI alerts
High impacting Denali Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
DNLI
News
- Denali Therapeutics (DNLI) had its price target raised by Robert W. Baird from $32.00 to $34.00. They now have an "outperform" rating on the stock.MarketBeat
- Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN) [Yahoo! Finance]Yahoo! Finance
- Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)GlobeNewswire
- This rare disease destroys a child's ability to walk and speak. Could a new drug help? [MSNBC.com]MSNBC.com
- They're in a race to save their children with a rare disease. A newly approved drug has given them hope. [MSNBC.com]MSNBC.com
DNLI
Earnings
- 2/26/26 - Beat
DNLI
Sec Filings
- 4/3/26 - Form 8-K
- 3/31/26 - Form 8-K
- 3/26/26 - Form SCHEDULE
- DNLI's page on the SEC website